Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Xaar revenue rises, adjusted losses widen slightly

(Sharecast News) - Xaar reported higher first-half revenue on Tuesday, driven by strong growth in its printhead business, as it said it remained on track to meet full-year expectations despite tariff-related headwinds affecting part of the group. Revenue for the six months ended 30 June rose 7% year-on-year to £27.2m, with printhead sales up 20% to £19.9m, accounting for 73% of the total.

Growth was led by a jump in jewellery wax revenue to £3.3m from £0.6m a year earlier, while printhead operating margin improved 70 basis points to 10.4%.

Engineered print systems (EPS) revenue fell 16% to £6.3m, reflecting delayed capital investment due to tariff uncertainty, though Xaar said the order pipeline is now recovering.

Gross margin slipped slightly to 36.5%, while adjusted EBITDA declined 15% to £0.76m.

The London-listed firm said its adjusted loss before tax widened marginally to £0.7m, as its statutory loss came in at £3.1m, compared with £2.6m in the first half of 2024, with net cash down to £5.1m following investment in equipment and development.

"The start of 2025 has been encouraging with the swift progress made in the jewellery wax market, reflecting the disruptive impact our technology will have in our target markets once OEM products have been launched," said chief executive John Mills.

"Opportunities in EV battery coating, automotive coating and desktop 3D are setting the Group up for sustainable medium-term growth with key developments within each market progressing as planned."

Xaar reiterated that revenue would be weighted towards the second half, with further growth in printhead sales expected, while EPS performance would remain affected by tariffs until the pipeline rebuilt.

The company said medium-term prospects were supported by maturing recent product launches and upcoming developments, with management confident of meeting current market expectations.

At 1021 BST, Xaar shares were down 4.18% at 114.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Thalia Therapeutics enters new phase of development
(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company.
Metir inks water system deal with Portsmouth Aviation
(Sharecast News) - Metir announced Friday that it has signed a memorandum of understanding with Portsmouth Aviation to evaluate integrated water treatment and monitoring systems combining Portsmouth's PaquaVida purification platform with Metir's Modern Water Microtox biological monitoring technology.
System1 reiterates rejection of Brave Bison's revised offer
(Sharecast News) - System1 reiterated its unanimous rejection of Brave Bison's revised cash-and-share proposal on Friday, saying feedback from major shareholders supported the board's view that the offer materially undervalued the company.
ConocoPhillips to buy 42% stake in BP Iraq oil fields
(Sharecast News) - BP said on Friday that it has agreed terms for ConocoPhillips to buy a 42% interest in BP Energy Company of Kirkuk (BP ECKL).

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.